CL2016001952A1 - Formulación farmacéutica tópica que comprende 50 a 2.500 ui/ml de sal de heparina, menos de o igual a 30% v/v de agua, 0% a 30% v/v de un alcohol de cadena inferior; y no menos de 45% v/v de un vehículo miscible en agua seleccionado del grupo que comprende propilenglicol, glicerol, glicofurol, polietilenglicol, o sus mezclas, util en tromboflebitis venosa superficial. - Google Patents
Formulación farmacéutica tópica que comprende 50 a 2.500 ui/ml de sal de heparina, menos de o igual a 30% v/v de agua, 0% a 30% v/v de un alcohol de cadena inferior; y no menos de 45% v/v de un vehículo miscible en agua seleccionado del grupo que comprende propilenglicol, glicerol, glicofurol, polietilenglicol, o sus mezclas, util en tromboflebitis venosa superficial.Info
- Publication number
- CL2016001952A1 CL2016001952A1 CL2016001952A CL2016001952A CL2016001952A1 CL 2016001952 A1 CL2016001952 A1 CL 2016001952A1 CL 2016001952 A CL2016001952 A CL 2016001952A CL 2016001952 A CL2016001952 A CL 2016001952A CL 2016001952 A1 CL2016001952 A1 CL 2016001952A1
- Authority
- CL
- Chile
- Prior art keywords
- less
- glycerol
- water
- mixtures
- heparin
- Prior art date
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title abstract 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 title abstract 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 2
- 201000005060 thrombophlebitis Diseases 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008136 water-miscible vehicle Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
- 229960002897 heparin Drugs 0.000 abstract 2
- 229920000669 heparin Polymers 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 2
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 230000035807 sensation Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El objetivo buscado a través de la presente solicitud corresponde a la necesidad de proporcionar formulaciones tópicas de sales de Heparina que sean estables, capaces de proporcionar una mayor penetración local a través de la piel de la sal de heparina, una efectividad terapéutica mejorada, y al mismo tiempo proporcionar un excelente cumplimiento del paciente con una sensación agradable en la superficie de la piel, así como una cantidad reducida de efectos adversos, que sea efectiva en el tratamiento de tromboflebitis venosa superficial. Como solución proponen una formulación tópica de sales farmacéuticamente aceptables de Heparina que comprende: • 50 a 2.500 UI/ml de sales farmacéuticamente aceptables de Heparina; • Menos de o igual a 30% v/v de agua; • 10% a 30% v/v de un alcohol de cadena inferior, el que se selecciona de alcohol(es) con una longitud de cadena de carbono que varía desde C1 hasta C5 o mezclas de los mismos; y • No menos de un 45% v/v de un vehículo miscible en agua seleccionado del grupo que comprende propilenglicol, glicerol, glicofurol, polietilenglicol, o mezclas de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN475MU2014 | 2014-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001952A1 true CL2016001952A1 (es) | 2017-03-10 |
Family
ID=52684592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001952A CL2016001952A1 (es) | 2014-02-10 | 2016-08-02 | Formulación farmacéutica tópica que comprende 50 a 2.500 ui/ml de sal de heparina, menos de o igual a 30% v/v de agua, 0% a 30% v/v de un alcohol de cadena inferior; y no menos de 45% v/v de un vehículo miscible en agua seleccionado del grupo que comprende propilenglicol, glicerol, glicofurol, polietilenglicol, o sus mezclas, util en tromboflebitis venosa superficial. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9861655B2 (es) |
| EP (1) | EP3104839B1 (es) |
| JP (1) | JP6275877B2 (es) |
| KR (1) | KR101822133B1 (es) |
| CN (1) | CN106163498A (es) |
| AP (1) | AP2016009350A0 (es) |
| AR (1) | AR099333A1 (es) |
| AU (1) | AU2015213569B2 (es) |
| CA (1) | CA2938388C (es) |
| CL (1) | CL2016001952A1 (es) |
| CU (1) | CU24444B1 (es) |
| DK (1) | DK3104839T3 (es) |
| DO (1) | DOP2016000198A (es) |
| EA (1) | EA032200B1 (es) |
| EC (1) | ECSP16069947A (es) |
| IL (1) | IL246974B (es) |
| MA (1) | MA39304B1 (es) |
| MX (1) | MX357765B (es) |
| MY (1) | MY182620A (es) |
| NZ (1) | NZ722830A (es) |
| PE (1) | PE20161173A1 (es) |
| PH (1) | PH12016501500B1 (es) |
| TW (1) | TWI538697B (es) |
| UA (1) | UA118279C2 (es) |
| WO (1) | WO2015118512A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150036825A (ko) * | 2010-04-13 | 2015-04-07 | 나지브 바불 | 1-메틸-2''-6''-피페콜옥실리디드의 피부 약제학적 조성물 및 사용 방법 |
| CN112546061B (zh) * | 2021-02-25 | 2021-06-11 | 中南大学湘雅医院 | 一种肝素类药物组合物、喷鼻剂及其制备方法及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3323389A1 (de) * | 1983-06-29 | 1985-01-10 | B. Braun Melsungen Ag, 3508 Melsungen | Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden |
| JPH02207018A (ja) * | 1989-02-07 | 1990-08-16 | Kao Corp | 皮膚外用剤 |
| DE19536244A1 (de) | 1994-09-30 | 1996-04-04 | Juergen Dr Regenold | Pharmazeutische Zusammensetzung zur lokalen Applikation |
| IT1275955B1 (it) | 1995-03-22 | 1997-10-24 | Dompe Spa | Formulazioni farmaceutiche in forma di gel tissotropico |
| JPH10279466A (ja) * | 1997-04-07 | 1998-10-20 | Kose Corp | 外用剤 |
| US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| BRPI0101486B1 (pt) | 2001-04-17 | 2017-09-19 | Cristália Produtos Químicos Farmacêuticos Ltda. | Pharmaceutical composition for topic use containing heparin for the treatment of skin or mucosal injuries caused by burns |
| NZ577604A (en) * | 2006-11-15 | 2012-06-29 | Arthritis Relief Plus Ltd | Topical formulation and uses thereof |
| IT1400232B1 (it) * | 2010-05-07 | 2013-05-24 | Advance Holdings Ltd | Composizione farmaceutica topica comprendente eparina |
| CA2829241A1 (en) * | 2011-04-01 | 2012-10-04 | University Of Florida Research Foundation, Inc. | Thermo-sensitive, mucoadhesive or dermoadhesive, and penetration-enhancing formulations for topical delivery of therapeutics |
-
2015
- 2015-02-10 CA CA2938388A patent/CA2938388C/en active Active
- 2015-02-10 AU AU2015213569A patent/AU2015213569B2/en not_active Ceased
- 2015-02-10 MY MYPI2016702732A patent/MY182620A/en unknown
- 2015-02-10 US US15/116,060 patent/US9861655B2/en not_active Expired - Fee Related
- 2015-02-10 CN CN201580007796.6A patent/CN106163498A/zh active Pending
- 2015-02-10 PE PE2016001445A patent/PE20161173A1/es unknown
- 2015-02-10 AP AP2016009350A patent/AP2016009350A0/en unknown
- 2015-02-10 AR ARP150100384A patent/AR099333A1/es unknown
- 2015-02-10 NZ NZ722830A patent/NZ722830A/en not_active IP Right Cessation
- 2015-02-10 CU CU2016000119A patent/CU24444B1/es unknown
- 2015-02-10 JP JP2016568157A patent/JP6275877B2/ja not_active Expired - Fee Related
- 2015-02-10 DK DK15710252.6T patent/DK3104839T3/da active
- 2015-02-10 TW TW104104460A patent/TWI538697B/zh not_active IP Right Cessation
- 2015-02-10 MX MX2016010399A patent/MX357765B/es active IP Right Grant
- 2015-02-10 WO PCT/IB2015/050986 patent/WO2015118512A1/en not_active Ceased
- 2015-02-10 EP EP15710252.6A patent/EP3104839B1/en active Active
- 2015-02-10 EA EA201691596A patent/EA032200B1/ru unknown
- 2015-02-10 KR KR1020167023895A patent/KR101822133B1/ko not_active Expired - Fee Related
- 2015-02-10 MA MA39304A patent/MA39304B1/fr unknown
- 2015-02-10 UA UAA201608842A patent/UA118279C2/uk unknown
-
2016
- 2016-07-27 IL IL246974A patent/IL246974B/en active IP Right Grant
- 2016-07-28 PH PH12016501500A patent/PH12016501500B1/en unknown
- 2016-08-02 CL CL2016001952A patent/CL2016001952A1/es unknown
- 2016-08-03 DO DO2016000198A patent/DOP2016000198A/es unknown
- 2016-08-26 EC ECIEPI201669947A patent/ECSP16069947A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR133768A2 (es) | Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
| MX2016008201A (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf. | |
| CL2017002939A1 (es) | Composiciones farmacéuticas tópicas | |
| GT201200069A (es) | Formulaciones farmacéuticas muy concentradas | |
| MX387604B (es) | Formulaciones cannabinoides estables. | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
| MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
| CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
| CL2019002172A1 (es) | Agente terapéutico para enfermedades del hígado. | |
| AR096402A1 (es) | Medicamento de metformina y dihidroquercetina | |
| ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| UY36202A (es) | Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer | |
| CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
| EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| AR094291A1 (es) | Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla | |
| MX2018001989A (es) | Formulaciones farmaceuticas. | |
| CL2020001738A1 (es) | Preparación de absorción percutánea para el tratamiento de la demencia que contiene donepezilo. | |
| CL2018003268A1 (es) | Ácidos carboxílicos para tratar/prevenir una enfermedad de la piel. | |
| PE20171305A1 (es) | Formulaciones inyectables de paracetamol |